Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Global Clinical Trials Review, H2, 2015
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Global Clinical Trials Review, H2, 2015 BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers. We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document. We look forward to being of service to you. If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf. Phone: +44 (0)1300 321501 or Email: reportstore@bioportfolio.com 2
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Global Clinical Trials Review, H2, 2015 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Global Clinical Trials Review, H2, 2015 Summary GlobalData's clinical trial report, Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Global Clinical Trials Review, H2, 2015" provides an overview of Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) clinical trials scenario. This report provides top line data relating to the clinical trials on Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for inprogress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData s proprietary database - Pharma etrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. *Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months *Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Reasons to buy - Assists in formulating key business strategies with regards to investment 3
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level *Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Additional Details Publisher : Global Data Reference : GDHC3101CTIDB Number of Pages : 50 Report Format : PDF Publisher Information : 4
Table Of Contents for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Global Clinical Trials Review, H2, 2015 Table of ContentsTable of Contents 2List of Tables 3List of Figures 4Report Guidance 5Clinical Trials by Region 6Clinical Trials and Average Enrollment by Country 7Top Countries Contributing to Clinical Trials in Asia-Pacific 10Top Five Countries Contributing to Clinical Trials in Europe 11Top Countries Contributing to Clinical Trials in North America 12Top Countries Contributing to Clinical Trials in Middle East and Africa 13Clinical Trials by G7 Countries: Proportion of Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) to Central Nervous System Clinical Trials 14Clinical Trials by Phase in G7 Countries 16Clinical Trials in G7 Countries by Trial Status 17Clinical Trials by E7 Countries: Proportion of Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) to Central Nervous System Clinical Trials 18Clinical Trials in E7 Countries by Trial Status 20Clinical Trials by Phase 21In Progress Trials by Phase 22Clinical Trials by Trial Status 23Clinical Trials by End Point Status 24Subjects Recruited Over a Period of Time 25Clinical Trials by Sponsor Type 26Prominent Sponsors 27Top Companies Participating in Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials 28Prominent Drugs 30Clinical Trial Profile Snapshots 31Appendix 47Abbreviations 47Definitions 47Research Methodology 48Secondary Research 48About GlobalData 49Contact Us 49Disclaimer 49Source 50 5
List Of Tables in Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Global Clinical Trials Review, H2, 2015 List of Tables Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials by Region, 2015* 6 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2015* 10 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, North America, Top Countries, 2015* 12 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 13 Proportion of Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) to Central Nervous System Clinical Trials, G7 Countries (%), 2015* 15 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17 Proportion of Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) to Central Nervous System Clinical Trials, E7 Countries (%), 2015* 19 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials by Phase, 2015* 21 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 22 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 25 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 26 6
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 27 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 29 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 30 7
List Of Figures, Charts and Diagrams in Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Global Clinical Trials Review, H2, 2015 List of Figures Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials by Region (%), 2015* 6 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12 Proportion of Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) to Central Nervous System Clinical Trials, G7 Countries (%), 2015* 14 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17 Proportion of Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) to Central Nervous System Clinical Trials, E7 Countries (%), 2015* 18 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials by Phase (%), 2015* 21 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 22 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 25 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 26 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 27 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 28 8
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 30 GlobalData Methodology 48 9
How to Buy... Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Global Clinical Trials Review, H2, 2015 Option 1 - Online Go to our website and pay online with any major debit or credit card: Option 2 - Request a Proforma Invoice Fill in the details below, and either Scan this page and email it to us at reportstore@bioportfolio.com or Fax it to us at +44 (0)1305 791844.We will send you a Proforma Invoice and deliver your report on settlement. Your Name: Job Title: Your Email: Your Contact Phone: Company Name: Address: Post/Zip Code: Country: P.O. Number: Any Other Instructions: Pricing Options: (please tick one) $2500 Single User Price $5000 Site License Price $7500 Enterprise License Price Payment Options: (please tick one) Online Credit Card (we will email you the invoice with a payment link) Direct Wire Transfer (we will email you the invoice with our bank details) Authorising Signature: Option 3 - Phone Us on +44 (0)1300 321501 We will be delighted to give you our personal attention. 10